NASDAQ:XNCR Xencor Q1 2026 Earnings Report $11.31 +0.04 (+0.35%) Closing price 04:00 PM EasternExtended Trading$11.29 -0.02 (-0.18%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Xencor EPS ResultsActual EPS-$1.71Consensus EPS -$0.75Beat/MissMissed by -$0.96One Year Ago EPS-$0.66Xencor Revenue ResultsActual Revenue$4.52 millionExpected Revenue$27.86 millionBeat/MissMissed by -$23.34 millionYoY Revenue Growth-86.20%Xencor Announcement DetailsQuarterQ1 2026Date5/6/2026TimeBefore Market OpensConference Call DateWednesday, May 6, 2026Conference Call Time4:00PM ETUpcoming EarningsXencor's Q2 2026 earnings is estimated for Wednesday, August 5, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, August 4, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Xencor Earnings HeadlinesXencor IncMay 18, 2026 | money.usnews.comXencor (XNCR) Receives a Buy from Wells FargoMay 15, 2026 | theglobeandmail.comPorter flew 3,300 miles to investigate this systemPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.May 22 at 1:00 AM | Porter & Company (Ad)Xencor, Inc. Common Stock (XNCR)May 13, 2026 | nasdaq.comXencor, Inc. (XNCR) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comJPMorgan Chase & Co. Issues Positive Forecast for Xencor (NASDAQ:XNCR) Stock PriceMay 12, 2026 | americanbankingnews.comSee More Xencor Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Xencor? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xencor and other key companies, straight to your email. Email Address About XencorXencor (NASDAQ:XNCR) is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins. The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics. Xencor’s pipeline features multiple clinical-stage candidates, including bispecific molecules that recruit T cells to tumor cells and antibody therapeutics targeting checkpoint pathways. The company also explores next-generation cytokine fusions designed to improve safety and efficacy profiles over conventional formats. In advancing its discovery programs, Xencor has established strategic collaborations and licensing agreements with several leading pharmaceutical companies. Partners include Amgen, Pfizer, AstraZeneca and Lilly, among others, which leverage Xencor’s XmAb® platform to generate novel candidates across oncology, inflammation and immunology. Through these partnerships, Xencor’s technology reaches global markets via co-development and commercial licensing arrangements. Founded in 1997 and headquartered in Monrovia, California, Xencor is led by President and Chief Executive Officer Bassil Dahiyat, Ph.D., who co-founded the company with a vision to harness protein engineering for therapeutic innovation. Over its history, Xencor has grown from a technology-focused startup into a specialized biotech organization advancing multiple clinical programs toward regulatory milestones.View Xencor ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Overextended, e.l.f. Beauty Is Primed to Rebound in Back HalfDeere Beats Q2 Estimates, But Ag Weakness Weighs on OutlookNVIDIA Price Pullback? Don’t Count on It, Business Is AcceleratingMeta Platforms 10% Layoff Raises a Bigger Question About AI SpendingBiogen Stock Slides After Trial Miss, But Analysts Stay BullishTarget Shows Strengths, But Analysts Want to See MoreLowe's Finds Support at $215 After Q1 Earnings Sell-Off Upcoming Earnings AutoZone (5/26/2026)Marvell Technology (5/27/2026)PDD (5/27/2026)Synopsys (5/27/2026)Bank Of Montreal (5/27/2026)Bank of Nova Scotia (5/27/2026)Salesforce (5/27/2026)Snowflake (5/27/2026)Autodesk (5/28/2026)Costco Wholesale (5/28/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
